Adjuvant conditioning induces an immunosuppressive milieu that delays alloislet rejection through the expansion of myeloid-derived suppressor cells.
MDSC
immunosuppression
innate immunity
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
23
03
2023
accepted:
12
04
2023
pmc-release:
01
07
2024
medline:
4
7
2023
pubmed:
21
4
2023
entrez:
20
04
2023
Statut:
ppublish
Résumé
Advances in immunosuppression have been relatively stagnant over the past 2 decades, and transplant recipients continue to experience long-term morbidity associated with immunosuppression regimens. Strategies to reduce or eliminate the dosage of immunosuppression medications are needed. We discovered a novel administration strategy using the classic adjuvant alum to condition murine islet transplant recipients, known as adjuvant conditioning (AC), to expand both polymorphonuclear and monocytic myeloid-derived suppressive cells (MDSCs) in vivo. These AC MDSCs potently suppress T cell proliferation when cultured together in vitro. AC MDSCs also facilitate naïve CD4
Identifiants
pubmed: 37080464
pii: S1600-6135(23)00413-6
doi: 10.1016/j.ajt.2023.04.015
pmc: PMC10330215
mid: NIHMS1895372
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
935-945Subventions
Organisme : NIAID NIH HHS
ID : L40 AI164513
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007754
Pays : United States
Informations de copyright
Copyright © 2023 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.
Références
Cell Rep. 2016 Dec 20;17(12):3219-3232
pubmed: 28009291
Trends Immunol. 2022 Jan;43(1):8-21
pubmed: 34844848
Front Immunol. 2022 Feb 04;13:746889
pubmed: 35185868
Innate Immun. 2019 Jan;25(1):46-59
pubmed: 30782043
Oncoimmunology. 2016 Oct 20;5(12):e1247135
pubmed: 28123883
J Immunol. 2014 Jun 15;192(12):6111-9
pubmed: 24829407
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Transplantation. 2011 May 27;91(10):1057-64
pubmed: 21412186
Transplantation. 2020 Mar;104(3):467-475
pubmed: 31596739
J Immunol. 2011 Jan 1;186(1):195-202
pubmed: 21106855
Liver Transpl. 2017 Feb;23(2):244-256
pubmed: 27874250
Am J Transplant. 2021 Feb;21 Suppl 2:208-315
pubmed: 33595192
Cancer Immunol Immunother. 2022 Sep;71(9):2255-2266
pubmed: 35129637
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Oncoimmunology. 2012 Nov 1;1(8):1433-1434
pubmed: 23243619
Am J Transplant. 2017 Jun;17(6):1656-1662
pubmed: 28296255
Front Immunol. 2020 Jan 22;10:3070
pubmed: 32038621
Am J Transplant. 2020 Sep;20(9):2343-2355
pubmed: 32282980
PLoS One. 2018 Feb 7;13(2):e0192197
pubmed: 29415028
Cancers (Basel). 2021 Jan 08;13(2):
pubmed: 33430105
Int J Mol Sci. 2018 Aug 10;19(8):
pubmed: 30103447
Mol Med. 2011 Mar-Apr;17(3-4):281-92
pubmed: 21085745
J Immunol Res. 2018 Jul 3;2018:5414808
pubmed: 30057917
Transplant Proc. 2011 Jul-Aug;43(6):2135-6
pubmed: 21839214
J Immunol. 2007 Jul 15;179(2):977-83
pubmed: 17617589
Am J Transplant. 2021 Feb;21 Suppl 2:21-137
pubmed: 33595191
Front Cell Dev Biol. 2022 Jan 21;9:759691
pubmed: 35127700
Cancer Res. 2008 Jul 1;68(13):5439-49
pubmed: 18593947
Am J Transplant. 2012 Dec;12(12):3449-61
pubmed: 22994804
Clin Exp Immunol. 2015 Mar;179(3):485-99
pubmed: 25302741